天目药业: 杭州天目山药业股份有限公司投资者关系管理制度（2025年8月修订）

Core Viewpoint - The investor relations management system of Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd. aims to enhance communication between the company and its investors, ensuring compliance with legal regulations and promoting transparency and trust [1][2][3]. Summary by Sections General Principles - The investor relations management is designed to facilitate the exercise of shareholder rights, information disclosure, interactive communication, and handling of investor requests [2]. - The basic principles include compliance, equality, proactivity, and honesty [2]. Objectives of Investor Relations Management - The objectives include improving communication with investors, establishing a stable investor base, enhancing corporate culture, increasing transparency in information disclosure, and maximizing overall and shareholder interests [3]. Communication Content - Key communication topics include the company's development strategy, legal information disclosures, operational management information, risks and challenges, corporate culture, and shareholder rights [3][4]. Communication Methods - Various communication methods are employed, including designated media for information disclosure, company website, performance briefings, one-on-one communications, and investor meetings [5][7]. Investor Meetings - The company is required to hold investor meetings under specific circumstances, such as when cash dividends do not meet regulations or when there are significant market events [8][12]. Responsibilities of the Board Secretary - The board secretary is responsible for managing investor relations, organizing communication activities, and ensuring timely responses to investor inquiries [10][11]. Training and Compliance - The company provides training for personnel involved in investor relations and ensures compliance with information disclosure regulations [12][13]. Prohibited Actions - Certain actions are prohibited during investor relations activities, including disclosing undisclosed significant information, providing misleading information, and unfair treatment of minority shareholders [13][14].